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Abstract 
Objectives: Dermal fibroblasts from patients with systemic sclerosis (SSc) release excessive 
amounts of collagen resulting in tissue fibrosis. The molecular mechanisms underlying this 
pathologic activation are incompletely understood. This study aimed to investigate whether 
Notch signaling contributes to the uncontrolled activation of fibroblasts in SSc. 
Methods: Activation of the Notch pathway was assessed by immunohistochemistry or 
Western Blot for the Notch intracellular domain (NICD) and the Notch ligand Jagged-1 (Jag-
1) and real-time PCR for the target gene hes-1. Differentiation of resting dermal fibroblasts 
into myofibroblasts was assessed by staining for α-smooth muscle actin and stress fibers. The 
synthesis of collagen was quantified by real-time PCR and SirCol assays. 
Results: Notch signaling was activated in lesional skin of SSc patients. The activation 
persisted in cultured dermal SSc fibroblasts. Stimulation of healthy dermal fibroblasts with 
recombinant human Jag-1-Fc chimera resulted in an SSc-like phenotype with increased 
release of collagen and differentiation of resting fibroblasts into myofibroblasts. Consistent 
with the selective activation of the Notch pathway in dermal SSc fibroblasts, DAPT or siRNA 
against Notch strongly reduced the basal collagen expression in SSc fibroblasts, but not in 
fibroblasts from healthy volunteers. 
Conclusion: We demonstrated that Notch signaling is activated in SSc and plays an important 
role in fibroblast activation and collagen release. Inhibition of Notch signaling might be an 
effective strategy to selectively prevent the aberrant activation of SSc fibroblasts.  
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Introduction 
 The major histopathologic hallmark of SSc is an excessive accumulation of 
extracellular matrix proteins.[1, 2] The molecular mechanisms underlying the pathologic 
activation of SSc fibroblasts have only partially been elucidated. 
Notch signaling, first discovered in Drosophila, is essential for cell fate decision and 
development.[3, 4] Activation of the Notch pathway by binding of ligands such as Jagged-1 
(Jag-1) results in cleavage of Notch receptors by the γ-secretase complex with subsequent 
release of the active Notch intracellular domain (NICD).[3] Two families of canonical Notch 
ligands have been described (Jagged and Delta-like), which seem to have distinct function.[5, 
6] As described for T helper cell differentiation, Jagged induces Th2 response, whereas Delta-
like, mainly Dll-4, is responsible for Th1 differentiation.[5] These ligands can interact with 
Notch receptors on both the surface of another cell (trans-interaction) and of the same cell 
(cis-interaction).[6] In contrast to the trans-interaction, cis-interactions seem to inhibit Notch 
signaling. The mechanisms and effects of cis-interactions, however, are still unkown.[6] In 
addition to the canonical ligands, several non-canonical ligands such as CCN3, MAGP-1 and 
MAGP-2 have been described.[6] Translocation of the NICD into the nucleus activates the 
transcription of target genes such as the Hairy/Enhancer of Split (Hes).[7] Alterations in 
Notch signaling are implicated in the pathogenesis of several human diseases such as T cell 
acute lymphoblastic leukemia (T-ALL), melanoma and Alagille syndrome.[8-11] Clinical 
trials with γ-secretase inhibitors in patients with T-ALL already yielded promising results.[12] 
The present study aimed to investigate whether Notch signaling may promote 
fibroblast activation and persistently increased release of collagen in SSc.  
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Material and Methods 
Fibroblast cultures 
Dermal fibroblast cultures were obtained from skin biopsies of SSc patients. All 
patients fulfilled the criteria for SSc as suggested by LeRoy et al.[13] Biopsies from SSc 
patients (n = 10) were taken from involved skin of the forearm (supplementary Table 1). 
Control dermal fibroblasts (n = 10) were obtained from forearm skin biopsies of healthy age- 
and sex-matched volunteers. Dermal fibroblasts from passages 4-8 were used for the 
experiments. All patients and controls signed a consent form approved by the local 
institutional review boards. 
 
Stimulation of dermal fibroblasts with Jag-1 and inhibition of Notch signaling 
Confluent dermal fibroblasts were cultured in DMEM containing 0.1 % FCS for 24 h 
before the experiments. Dermal fibroblasts were stimulated with recombinant human Jag-1 Fc 
Chimera (R&D Systems, Minneapolis, MN, USA) dissolved in PBS in concentrations from 
0.04 to 5.0 µg/ml for 24 h. 
 To assess the effects of Notch signaling inhibition, dermal fibroblasts were incubated 
with the γ-secretase inhibitor N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-
butyl ester (DAPT) (Sigma-Aldrich, Steinheim, Germany) at concentrations of 1.0 and 10 µM 
for 24 h. Jag-1 was added one hour after DAPT at a concentration of 5.0 µg/ml. 
In addition to DAPT, dermal SSc fibroblasts were transfected with 1.5 µg siRNA 
against Notch-1 using the human dermal fibroblast Nucleofector Kit (Amaxa, Cologne, 
Germany) (supplementary Table 2).[14] Fibroblasts transfected with control siRNA (Ambion, 
Darmstadt, Germany) served as controls. Cells were harvested after 48 h. 
 
mRNA-stability assay 
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 To investigate whether Jag-1 stabilizes collagen mRNA, mRNA-stability assay was 
performed as previously described.[15]  
 
Luciferase reporter assay 
The -353 col1a2 / luciferase construct was kindly provided by M. Trojanowska.[15] 
HEK293T cells were transfected in serum-free medium with 0.5 µg reporter construct mixed 
with polyethyleneimine (PEI). A common lacZ reporter vector was used as control. Cells 
were stimulated with Jag-1 directly after the transfection. The luciferase activity was analyzed 
after 24 h. 
 
Quantitative real time PCR   
Total RNA was isolated with the NucleoSpin RNA II extraction system (Machery-
Nagel, Düren, Germany) and converted into cDNA as described.[16] In skin samples, the 
epidermal and dermal layers were separated for RNA isolation. The primer pairs used for real-
time PCR are given in Supplementary Table 2. A pre-developed β-actin assay (Applied 
Biosystems) was used to normalize for the amounts of loaded cDNA. All samples were 
measured in duplicates. 
 
Quantification of soluble collagen protein 
 Total soluble collagen in cell culture supernatants was quantified using the SirCol 
collagen assay (Biocolor, Belfast, Northern Ireland) as described.[17] 
 
Immunohistochemistry for Jag-1, CD3 and the NICD  
Fresh frozen sections of forearm skin from SSc patients (n = 13; supplementary Table 
3) and healthy individuals (n = 10) were used for immunohistochemical analyses (see 
Supplementary Methods).  
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Immunofluorescence for α-smooth muscle actin and the NICD 
 Fibroblasts stimulated with Jag-1-Fc (5 µg/ml) were incubated with monoclonal anti-
αSMA antibodies (clone 1A4, Sigma-Aldrich, Steinheim, Germany) and polyclonal rabbit-
anti-human NICD (Abcam, Cambridge, UK). TRITC conjugated goat anti-mouse antibodies 
and FITC conjugated goat anti-rabbit antibodies (Invitrogen, Karlsruhe, Germany) served as 
secondary antibodies. Counterstaining was performed with DAPI (Santa Cruz 
Biotechnologies, Santa Cruz, CA, USA) for ten minutes at room temperature. 
 
Western Blot 
Whole cell lysates were prepared as previously described.[18] PVDF membranes were 
incubated with polyclonal rabbit-anti Notch-1 (Abcam, Cambridge, UK) or polyclonal rabbit-
anti activated Notch-1 (Abcam, Cambridge, UK). Horseradish peroxidase-conjugated 
polyclonal goat anti-rabbit antibodies (DAKO, Hamburg, Germany) were used as secondary 
antibodies. Equal loading of proteins was confirmed by visualization of α-tubulin 
(Invitrogen). 
 
Statistics 
Data are expressed as mean ± standard error of the mean. The Wilcoxon signed rank 
tests for related samples and the Mann-Whitney-U-test for non-related samples were used for 
statistical analyses. A p-value of less than 0.05 was considered statistically significant. 
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Results 
Notch signaling is activated in lesional skin of SSc patients 
We first analyzed the expression of the four Notch receptors in dermal fibroblasts. The 
levels of Notch-1 mRNA were significantly increased in SSc fibroblasts as compared to 
controls (Supplementary Figure 1). Notch-2 was detectable, but in contrast to Notch-1, its 
levels did not differ between SSc and controls. Notch-3 and Notch-4 were not detectable by 
real-time PCR in dermal fibroblasts as these receptors are predominantly expressed in 
vascular smooth muscle cells and vascular endothelial cells.[19] 
To investigate whether Notch signaling is activated in lesional skin of SSc patients, we 
stained for the NICD, which is only released upon ligand binding to Notch and therefore is a 
marker for activation of the Notch pathway.[3] The NICD was almost undetectable in healthy 
individuals (Figure 1a). In contrast, we observed an intensive staining in all SSc patients, 
particularly in fibroblasts of the papillary dermis (Figure 1a). Staining for the NICD, however, 
was not restricted to fibroblasts and was also prominent in keratinocytes, endothelial cells, 
pericytes, vascular smooth muscle cells and T cells as described before (Figure 1a).[20] 
Consistent with increased Notch signaling, the mRNA levels of the Notch target gene hes-1 
were elevated by 392 ± 33 % in skin biopsies of SSc patients as compared to skin biopsies 
from healthy individuals (p < 0.05) (Figure 1b). To investigate the mechanisms that activate 
Notch signaling in SSc, we analyzed the expression of Notch ligands and observed an 
upregulation of Jag-1 mRNA levels by 608 ± 86 % in SSc skin compared to control skin 
samples (p < 0.05) (Figure 1c). Expression of Jag-1 protein was detected in epidermis and 
dermis of all SSc patients (Figure 1d). A prominent expression of Jag-1 was observed in 
inflammatory infiltrates in fibrotic skin. Double-staining for Jag-1 and CD3 showed elevated 
Jag-1 expression particularly in T cells (Figure 1e). In contrast to SSc patients, no significant 
expression of Jag-1 was detected in healthy individuals.  
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Persistent activation of the Notch pathway in cultured SSc fibroblasts 
Of particular interest, the increased activation of the Notch pathway in dermal SSc 
fibroblasts persisted in vitro. A significant accumulation of the NICD occurred in SSc 
fibroblasts, whereas the NICD was barely detectable in fibroblasts from healthy individuals 
(Figure 2a). Consistently, the mRNA levels of hes-1 were upregulated in cultured SSc 
fibroblasts in passages 4 to 8 with increases of 375 ± 50 % compared to fibroblasts from 
healthy individuals (p < 0.05) (Figure 2b). 
 
Jag-1 stimulates the release of extracellular matrix  
To investigate whether the overexpression of Jag-1 and the increased activation of the 
Notch pathway contribute to the aberrant production of extracellular matrix, healthy dermal 
fibroblasts were stimulated with recombinant Jag-1.[21, 22] Activation of the Notch pathway 
upon stimulation with Jag-1-Fc was confirmed by a dose-dependent increase in hes-1 mRNA 
levels (Figure 3a). Jag-1 upregulated dose-dependently the expression of extracellular matrix 
components reaching a maximum at concentrations of 5 µg / ml (Figures 3b-d). Stimulation 
with Jag-1-Fc increased the mRNA levels of col 1a1 and col 1a2 to 294 ± 37 % and 217 ± 28 
%, respectively (p < 0.05) (Figure 3b and 3c). Consistent with the results on the mRNA level, 
collagen protein in cell culture supernatants increased to 259 ± 32 % upon stimulation with 
Jag-1-Fc as assessed by the SirCol assay (p < 0.05) (Figure 3d). 
To discriminate between increased gene transcription and altered mRNA stability in 
response to stimulation with Jag-1-Fc, we performed mRNA stability and reporter assays. The 
relative changes in mRNA levels of extracellular matrix proteins did not differ between Jag-1-
Fc stimulated fibroblasts and controls over time upon incubation with actinomycin D, 
suggesting that Jag-1-Fc does not increase mRNA stability (supplementary Figure 2a). In 
contrast, Jag-1-Fc stimulated collagen transcription by 173 ± 12 % as analyzed by a luciferase 
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expression vector under the control of the col 1a2 promoter (p < 0.05) (supplementary Figure 
2b). 
 
Jag-1 induces differentiation of resting fibroblasts into myofibroblasts 
 Myofibroblasts play an important role in the pathogenesis of fibrotic diseases. They 
are identified by the expression of contractile proteins such as αSMA. Upon stimulation with 
Jag-1-Fc, the mRNA levels of αSMA increased dose-dependently by 239 ± 37 % (p < 0.05) in 
normal dermal fibroblasts (Figure 4a). Intensive staining for αSMA protein and for the NICD 
was observed in Jag-1-Fc stimulated healthy fibroblasts as analyzed by immunofluorescence 
(Figure 4b). The percentage of double positive cells increased from 19 % in unstimulated 
control cells to 82 % in Jag-1-Fc stimulated fibroblasts, whereas only 3 % of the cells were 
positive for the NICD but negative for αSMA, and 6 % of the cells were negative for the 
NICD but positive for αSMA. Together, these data suggested that Jag-1-Fc stimulates 
differentiation of resting fibroblasts into myofibroblasts. 
 
DAPT effectively reduces the stimulatory effects of Jag-1 
 The activity of γ-secretase is essential for the activation of Notch signaling. To 
evaluate the effects of the γ-secretase inhibitor DAPT on the release of extracellular matrix, 
we incubated Jag-1 stimulated healthy dermal fibroblasts with DAPT at pharmacologically 
relevant concentrations.[23, 24] DAPT inhibited the mRNA expression of col 1a1 in healthy 
dermal fibroblasts stimulated with Jag-1-Fc dose-dependently by up to 99 ± 23 % (p < 0.05) 
(supplementary Figure 3a). Similar effects were obtained for col 1a2 (p < 0.05) 
(supplementary Figure 3b). Consistent with reduced mRNA levels, the release of collagen 
protein was reduced by 94 ± 34 % upon pretreatment with DAPT (p < 0.05) (supplementary 
Figure 3c). 
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Inhibition of Notch signaling reduces the basal collagen synthesis specifically in SSc 
fibroblasts 
We demonstrated a persistent activation of the Notch pathway in cultured fibroblasts 
from SSc patients. To assess whether inhibition of the Notch pathway can inhibit the basal 
release of collagen, SSc fibroblasts were incubated with DAPT in the absence of Jag-1-Fc. 
Treatment of unstimulated SSc fibroblasts with DAPT reduced the mRNA levels of col 1a1 
and col 1a2 by up to 49 ± 9 % and 41 ± 6 %, respectively (p < 0.05 for both) (Figure 5a and 
b). The collagen content in the supernatants was reduced by up to 59 ± 11 % upon incubation 
with DAPT (p < 0.05) (Figure 5c). Consistent with the persistent activation of the Notch 
pathway in SSc fibroblasts, no effects of DAPT on collagen expression were detected in 
cultured fibroblasts from healthy individuals in the absence of exogenous Jag-1 (Figures 5a-
c). 
 To exclude off-target effects, we confirmed the anti-fibrotic effects of DAPT signaling 
by transfection of SSc fibroblasts with siRNA against Notch-1 which resulted in significantly 
decreased mRNA and protein levels of Notch-1 (p < 0.05) (Figure 6a). Knockdown of Notch-
1 efficiently reduced mRNA levels of col 1a1 and col 1a2 by 58 ± 11 % and 48 ± 9 % 
compared to mock transfected SSc fibroblasts (Figure 6b and c). Consistently, the release of 
collagen protein was reduced by 42 ± 8 % (p < 0.05) upon silencing of Notch-1 (Figure 6d). 
 11 
Discussion 
We demonstrate in the present study that Notch signaling is activated in SSc with a 
prominent expression of the ligand Jag-1 in infiltrating T cells and active Notch signaling 
with accumulation of the NICD in fibroblasts. We further showed that the activation of Notch 
signaling has major implications on the activation of fibroblasts. The expression patterns of 
Jag-1 and the NICD suggest that infiltrating T cells expressing Jag-1 might activate Notch 
signaling in resident fibroblasts. Jag-1 is prominently expressed in T cells in fibrotic skin. 
Direct cell-cell contact between T cells expressing the ligand Jag-1 and fibroblasts expressing 
high levels of Notch-1 may be the major mechanism for the activation of Notch signaling in 
SSc fibroblasts with accumulation of the NICD and increased transcription of target genes 
such as hes-1 in fibroblasts. Considering the potent stimulatory effects of Jag-1-Fc on cultured 
fibroblasts, T cell mediated activation of Notch signaling in fibroblasts might be an important 
mechanism for the aberrant activation of fibroblasts in SSc. However, further studies are 
needed to confirm this hypothesis and to further elucidate the molecular mechanism of this 
activation. Consistent with our findings of an increased activation of Notch signaling in SSc, 
Kavian et al recently demonstrated an activation of Notch signaling in SSc as well as in 
mouse models of dermal fibrosis. [25]  
We demonstrate that activation of Notch signaling induces a pro-fibrotic phenotype in 
resting dermal fibroblasts. Jag-1-Fc stimulates the release of collagen protein and induces 
differentiation of resting dermal fibroblasts into myofibroblasts. Consistent with the increased 
expression of contractile proteins observed in our study, Notch may also regulate migration of 
fibroblasts.[23] Thus, pathologic activation of Notch signaling stimulates resting dermal 
fibroblasts to express contractile proteins, differentiate into myofibroblasts and release 
excessive amounts of extracellular matrix proteins.  
Although evidence for the important role of Notch signaling is growing, it remains 
unclear how Notch signaling induces myofibroblast differentiation and stimulates the release 
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of collagen in fibrotic diseases on a molecular level. In this context, it is still obscure if hes-1 
induction is essential for these stimulatory effects. Notch signaling may also be induced under 
hypoxic conditions or by TGFβ.[26-28] Consistently, we have preliminary evidence that 
Notch-1 and hes-1 are increased in dermal fibroblasts upon stimulation with TGFβ or under 
hypoxia. In addition, NICD and pSmad3 seem to be co-expressed in skin of SSc patients. 
Moreover, recent work indicated that local production of reactive oxygen species might 
induce ADAM17, a protease involved in the activation of Notch signaling.[25] 
Finally, we demonstrated that inhibition of the Notch pathway by either 
pharmacological blockade of the γ-secretase complex or siRNA against Notch-1 exerted 
potent anti-fibrotic effects selectively in dermal SSc fibroblasts, whereas the basal collagen 
synthesis in healthy dermal fibroblasts was not affected by inhibition of Notch signaling. 
Thus, targeting Notch signaling might have the potential to selectively reduce the activation 
of dermal SSc fibroblasts without affecting the collagen synthesis in resting normal dermal 
fibroblasts. In addition, pharmacologic blockade of the γ-secretase complex might decrease 
the proliferation of SSc fibroblasts. Our in vitro findings are further extended by recent work 
from Kavian and coworkers.[25] Treatment with the γ-secretase inhibitor DAPT prevented 
development of experimental dermal as well as pulmonary fibrosis. In mice, DAPT 
significantly ameliorated the development of dermal and pulmonary fibrosis, decreased 
proliferation of fibroblasts, reduced the production of H2O2 and abrogated the production of 
anti-DNA topoisomerase-1 antibodies.[25] These findings might have translational 
implications as different inhibitors of the γ-secretase complex are in clinical trials for different 
types of cancer (www.clinicaltrials.gov). However, given the activation of Notch signaling in 
endothelial cells in our study and the role of Notch signaling in vascular homeostasis 
(reviewed in [29]), inhibition of Notch signaling might be hindered by anti-angiogenic effects 
in SSc patients suffering from extensive small-vessel vasculopathy with capillary 
rarifications. By contrast, inhibitors of the γ-secretase complex might be benficial in patients 
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with proliferative vasculopathies such as pulmonary arterial hypertension, because Notch-3 is 
activated in vascular smooth muscle cells (vSMCs) from PAH tissue and contributes to the 
increased proliferation of vSMCs.[30] 
In summary, Notch signaling is activated in lesional skin of SSc patients. Considering 
its potent stimulatory effects on dermal fibroblasts, Notch signaling might contribute to the 
pathologic activation of SSc fibroblasts. 
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Figure legends 
 
Figure 1: Notch signaling is activated in lesional skin of SSc patients. Figure 1a: An intensive 
staining for the Notch intracellular domain was observed in fibroblasts in skin sections of SSc 
patients, whereas the NICD was almost undetectable in skin sections of healthy individuals. 
Figure 1b: The Notch target gene hes-1 is overexpressed in lesional skin of SSc patients. 
Figure 1c: Increased mRNA levels of the Notch ligand Jag-1 in skin of SSc patients. Figure 
1d: Jag-1 is overexpressed in lesional skin of SSc patients. Figure 1e: Jag-1 expression is 
elevated in T cells of inflammatory infiltrates of fibrotic skin. 
n = 13 for SSc samples and n = 10 for healthy skin samples. Representative skin sections are 
shown at 200 fold (Figure 1a and d) or 400 fold (Figure 1e) magnification, fibroblasts are 
shown at 1000 fold magnification.  
* indicates statistical significant differences compared to skin samples from healthy controls. 
 
Figures 2: Persistent activation of the Notch pathway in SSc fibroblasts after long-term 
culture. Figure 2a: Elevated levels of the NICD in SSc fibroblasts as determined by Western 
blot (n = 3 each). Figure 2b: Increased mRNA levels of the target gene hes-1 (n = 8 for 
healthy fibroblasts, n = 6 for SSc fibroblasts). * indicates statistical significant differences 
compared to healthy dermal fibroblasts. 
 
Figure 3: Jag-1 stimulates the synthesis of collagen in fibroblasts. Stimulation of healthy 
dermal fibroblasts with Jag-1 at concentrations from 0.04 µg/ml to 5 µg/ml increased the 
mRNA levels of hes-1 (Figure 3a), col 1a1 (Figure 3b) and col 1a2 (Figure 3c) in a dose-
dependent manner. Consistently, Jag-1 stimulated the release of collagen protein (Figure 3d) 
(n = 8 each). * indicates statistical significant differences compared to unstimulated fibroblasts. 
 
 19 
Figure 4: Jag-1 induces differentiation of resting fibroblasts into myofibroblasts. Figure 4a: 
Jag-1 increased the mRNA levels of αSMA in a dose-dependent manner (n = 8). * indicates 
statistical significant differences compared to unstimulated fibroblasts. Figure 4b: Jag-1 
induced the release of NICD and the expression of αSMA protein in resting fibroblasts (n = 5). 
Representative examples are shown at 200 fold magnification.  
 
Figure 5: The γ-secretase inhibitor DAPT reduces the basal synthesis of extracellular matrix 
only in SSc fibroblasts. DAPT reduced the basal mRNA levels of col 1a1 (Figure 5a) and col 
1a2 (Figure 5b) and decreased the release of collagen protein (Figure 5c) in SSc fibroblasts 
(n = 7). In contrast, no effect of DAPT on the basal collagen expression was observed in 
healthy fibroblasts in the absence of exogenous Jag-1 (Figure 5a-c) (n = 6). * indicates 
statistical significant differences compared to untreated fibroblasts. 
 
Figure 6: Knockdown of Notch-1 by siRNA decreases collagen expression in SSc fibroblasts. 
Nucleofection of SSc fibroblasts with 1.5 µg of siRNA against Notch-1 efficiently reduced 
Notch-1 mRNA and protein (Figure 6a). Knockdown of Notch-1 decreased the mRNA levels 
of col 1a1 (Figure 6b) and col 1a2 (Figure 6c) and reduced the release of collagen (Figure 
6d) (n = 6 each). * indicates statistical significant differences compared to mock transfected 
fibroblasts. 
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Supplementary Figure legends 
 
Supplementary Figure 1: Expression of Notch receptors in dermal fibroblasts. Notch-1 and 
Notch-2 were expressed in dermal fibroblast, whereas Notch-3 and Notch-4 were not 
detectable by real-time PCR. However, only Notch-1, but not Notch-2 is overexpressed in 
dermal fibroblasts from SSc patients (n = 8 each). * indicates statistical significant differences 
compared to dermal fibroblasts from healthy volunteers.  
 
Supplementary Figure 2: Jag-1 stimulates the transcription of col1a2, but does not affect the 
half-life of col1a2 mRNA. Supplementary Figure 2a: The mRNA half-life of col 1a2 is not 
altered by Jag-1 (n = 3). Supplementary Figure 2b: Stimulation with Jag-1 increased the 
transcription of col1a2 in reporter assays (n = 5). * indicates statistical significant differences 
compared to unstimulated controls. 
 
Supplementary Figure 3: The γ-secretase inhibitor DAPT reduces the stimulatory effects of 
Jag-1 on the expression of extracellular matrix proteins. Pre-incubation with DAPT reduced the 
mRNA levels of col 1a1 (supplementary Figure 3a) and col 1a2 (supplementary Figure 3b) 
in healthy dermal fibroblasts stimulated with Jag-1. Similar results were obtained for the 
release of collagen protein (supplementary Figure 3c). (n = 8 each) * indicates statistical 
significant differences compared to fibroblasts stimulated with Jag-1. 
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Tables 
 
 
Gender 
(F/M) 
Age 
(median/range) 
Disease subset 
(limited/diffuse) 
Disease duration 
(median/range) 
Medications 
11/3 
49 years 
(33-74) 
9/5 
6 years 
(1 – 16) 
No DMARDs, 
Corticosteroids or NSAIDs  
Supplementary Table 1: Characteristics of SSc patients at date of biopsy for generation of 
dermal fibroblast cultures. F = female, M = male. The disease subset was determined 
according to the criteria proposed by LeRoy et al. Disease duration was measured from the 
onset of the first non-Raynaud symptoms attributable to SSc. DMARDS = (potentially) 
disease-modifying anti-rheumatic drugs, NSAIDS = non-steroidal anti-inflammatory drugs 
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